Precision Medicine

Peijia Medical submits its innovative GeminiOne heart valve repair system for EU approval, signaling a new challenge to established players in the market.

Johnson & Johnson unveils promising data for its next-gen AFib tech while reinforcing the safety of its current platform in a competitive market.

A European company with Big Pharma roots brings its natural allergy aid, SnizIQ, to California, tapping into a growing demand for alternatives.

With rapid trial enrollment for a novel drug, Pulmovant offers a potential lifeline for patients with PH-ILD, a condition with few to no options.

A new 7,500-participant study will test a cfDNA-based screen to identify high-risk pregnancies months before symptoms appear, a potential paradigm shift.

Manipal's new comprehensive cancer centre in South Bengaluru integrates robotic surgery, precision radiation, and holistic support to combat rising cancer rates.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

As Amwell prepares its 2025 results, investors watch to see if its strategic pivot to profitability can redefine the future of digital healthcare.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

A new drug from Bayer dramatically cuts recurrent stroke risk by 26% without the dangerous bleeding side effects of current therapies, offering hope to millions.

A new study reveals why Sickle Cell Disease patients suffer from frequent crises and rely on pain pills, even with awareness of multi-million dollar cures.

A new initiative unites top scientists to study 'SuperAgers' and resilient brains, aiming to unlock the secrets of healthy aging and prevent Alzheimer's.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

A new report reveals how GLP-1 drugs are accelerating a major healthcare shift in the Gulf, turning metabolic health into a core economic and policy issue.

A new partnership will integrate data from millions in India and the UAE, aiming to fix research bias and build more equitable AI-driven medicine.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

A simple nasal spray could offer immediate, broad protection against the flu. New landmark studies show how this antibody-based shield could revolutionize prevention.

A breakthrough program at Children's Hospital of Philadelphia is redefining heart pumps as tools for recovery, not just a bridge to transplant.

Wolters Kluwer's UpToDate again tops KLAS rankings, highlighting a major trend: integrating expert-backed patient education directly into clinical care.